QUESTION: Is there any data on non standard of care cancer patients using HDIVC alone?
ANSWER: There is not much out there (published) using HDIVC alone in cancer. This article has the three case series of remissions with HDIVC which is a paper we used to send around to other physicians in the early BIORC days. I think the reason IVC studies are less likely to be done without chemo or standard of care is twofold (or more fold…) one being getting approval for a human arm without Standard Of Care (SOC) therapy and the other being that very rarely is HDIVC used or viewed as a stand alone cancer therapy. I am trying to think and cannot come up with anyone in my cloudy memory who just employs HDIVC for cancer. It is an excellent modality for many things (in our experience improved QOL, some improved survival, enhancement of chemotherapy outcomes…) but unlikely really useful alone for very long.
For that reason when looking at what to include in the therapeutic interventions at AMSA, we have never (except for a small few) used HDIVC alone. That said we have a small group of people for whom SOC was contraindicated (age, comorbidity…) who opted for HDIVC Tx only, and they are all alive much to the surprise of their oncologists. Should time and my life span permit those cases may be written up.
Additionally when looking at groups getting just HDIVC or adding other therapies to enhance (i.e. IV Artesunate etc) the combination Tx always worked better – so in most it is hard to make a case for HDIVC as monotherapy. Most of the research now is aimed at whole practice outcomes research which in our case includes some patients on SOC oncology care, some past that and some never on it. In brief, it isn’t likely to happen (a monotherapy IV study on non SOC cancer patients using HDIVC alone) for many reasons.
